HM19 Satellite symposia schedule, information

Hepatology News Tonight: Managing complications of cirrhosis
Sunday, March 24
5:30 - 7:30 p.m., National Harbor 4-5
Registration starts at 5:30 p.m. Dinner Symposium 6:00 - 7:30 p.m.
Presenters:Robert S. Brown Jr., MD, MPH (Chair), Gladys and Roland Harriman professor of medicine, vice chair for mentorship and academic development, clinical chief of the division of gastroenterology & hepatology, Weill Cornell Medicine, New York; Kimberly Brown, MD, FAST, FAASLD, AGAF, professor of medicine at Wayne State University and chief of gastroenterology and hepatology and associate medical director, Henry Ford Hospital Transplant Institute, Henry Ford Hospital, both in Detroit; Steven Flamm, MD, FAASLD, FACG, chief, liver transplantation program, and professor of medicine and surgery, Northwestern University, Chicago.
Target Audience: This activity has been designed to meet the educational needs of physicians, advanced practice providers, and allied health professionals who provide care for hospitalized patients with liver disease.
Learning Objectives: After completing this program, participants should be better able to:

• Understand the complications and the consequences of cirrhosis.
• Describe the economic, patient, and caregiver burdens associated with cirrhosis.
• Demonstrate the ability to properly treat the complications of cirrhosis and prevent recurrence.

Accredited by: Rehoboth McKinley Christian Health Care Services
Provided by: Chronic Liver Disease Foundation. Supported by educational grants from Mallinckrodt Pharmaceuticals and Salix Pharmaceuticals.
Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the New Mexico Medical Society (NMMS) through the joint providership of Rehoboth McKinley Christian Health Care Services (RMCHCS), the Chronic Liver Disease Foundation, and the Texas Gulf Coast Gastroenterological Society. RMCHCS is accredited by the NMMS to provide continuing medical education for physicians. RMCHCS designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Americans with Disabilities Act: The event staff will be glad to assist you with any special needs (such as physical or dietary).
Registration: www.ChronicLiverDisease.org. On-site registration is available. Space is limited, so please arrive by 5:00 p.m. Seating is on a first-come, first-served basis.

An evidence-based approach to reducing stroke risk in nonvalvular atrial fibrillation
Sunday, March 24
5:30 - 7:30 p.m., Woodrow Wilson BC
Presenter:
Dharmesh Patel, MD, MBBS (London), FACC, FACP, FASPC, FNLA, Stern Cardiovascular Foundation; president of Alliance for Patient Access; past president American Heart Association; past chairman of medicine, Baptist Desoto Hospital, Southaven, Miss.; board member, AHA Southeast America, Memphis, Tenn.
Learning Objectives: This lecture will present options for reducing the risk of stroke in patients with nonvalvular atrial fibrillation.
Sponsored by: Janssen Pharmaceuticals.

Understanding your legal tools: The keys to lawsuit prevention, license protection and tax reduction
​​​​​​Monday, March 25
Noon - 1:00 p.m., National Harbor 2-3
Lunch provided at noon.
Objectives:

• Learn how to protect your license from negative reports to the NPDB following a settlement from your insurance company. If there is no NPD report, it’s unlikely that a board investigation into legal matters will materialize, preventing any sanctions from the state licensing board.
• Learn the best business structure for income tax reduction. Learn about the new tax laws passed in 2018 and how they can benefit you.
• Learn the use of legal tools that will protect your professional and personal assets from lawsuits. (Statistically, not even one in 100,000 are using these tools in the right way.)
• Learn how to protect business, property and personal assets in the event of a judgment in excess of liability insurance.
• Shows how to structure: C-corps, S-corps, FLPs, LLCs, etc. 

Faculty: Art McOmber
Sponsored by: Legally Mine.

Evidence-based approach to COPD management: Exploring new guidelines and treatment options for managing COPD exacerbations
Monday, March 257:00 - 9:30 p.m.,
Cherry Blossom Ballroom
Dinner provided at 7:00 p.m.
Learning Objectives: After completing this program, participants should be better able to do the following:

• Discuss considerations for reducing the risk of exacerbations in the inpatient and ambulatory setting.
• Raise awareness of strategies to improve COPD standardization of care across sites of care.
• Evaluate the role of long-acting bronchodilators to treat underlying pathophysiology of exacerbations.
• Understand the importance of inhaler selection when initiating maintenance therapy or reassessing treatment based on disease progression.

Faculty: Haley M. Hoy, PhD, ACNP, FAANP, The University of Alabama Huntsville, Vanderbilt Medical Center.
Sponsored by: Boehringer Ingelheim.

C. difficile infection: A hospitalist’s roadmap to treatment and prevention of recurrence 
Monday, March 25
7:00 - 9:00 p.m., National Harbor 2-3
Dinner provided at 7:00 p.m.
Program Overview: Clostridium difficile infection (CDI) places a significant clinical and economic burden on the health care system. The rising incidence of CDI is attributed to the emergence of a previously rare and hypervirulent strain of C. difficile. Increased toxin production and high-level antimicrobial resistance have allowed this strain to thrive in health care settings. Furthermore, populations previously thought to be at low risk of infection are now being identified as having severe CDI, including those without any exposure to health care facilities.

Fortunately, new diagnostic techniques have been developed to assist clinicians in the accurate and rapid detection of these infections. Additionally, new treatment options are available to clinicians for the management of initial and recurrent episodes of CDI. The prevention and management of CDI involve multiple disciplines responsible for the care of at-risk patients. As a key patient advocate in the hospital, the hospitalist can play a major role in ensuring that appropriate measures are in place for their patients at high risk for CDI. Hospitalists also can ensure that timely and appropriate diagnostic tests are performed at the early signs of CDI and that appropriate treatment selection is based on patient factors.
Faculty: William Ford, MD, SFHM, regional director hospital medicine and clinical associate professor of medicine, Abington (Penn.) Jefferson Health; Jason C. Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, clinical professor and clinical specialist, infectious diseases, and director, PGY2 Residency in Infectious Diseases Pharmacy, Temple University, Philadelphia; Ciaran P. Kelly, MD, professor of medicine, Harvard Medical School, and director, gastroenterology fellowship training and director, Celiac Center, Beth Israel Deaconess Medical Center, both in Boston.
Registration: www.vemcomeded.com/livemeetings.asp or call 908-704-2400.
Accreditation statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Center for Independent Healthcare Education (Center) and Vemco MedEd. Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit designation: Center designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supported by an educational grant from Merck & Co. Jointly provided by Center for Independent Healthcare Education and Vemco MedEd.

Hepatology News Tonight: Managing complications of cirrhosis
Sunday, March 24
5:30 - 7:30 p.m., National Harbor 4-5
Registration starts at 5:30 p.m. Dinner Symposium 6:00 - 7:30 p.m.
Presenters:Robert S. Brown Jr., MD, MPH (Chair), Gladys and Roland Harriman professor of medicine, vice chair for mentorship and academic development, clinical chief of the division of gastroenterology & hepatology, Weill Cornell Medicine, New York; Kimberly Brown, MD, FAST, FAASLD, AGAF, professor of medicine at Wayne State University and chief of gastroenterology and hepatology and associate medical director, Henry Ford Hospital Transplant Institute, Henry Ford Hospital, both in Detroit; Steven Flamm, MD, FAASLD, FACG, chief, liver transplantation program, and professor of medicine and surgery, Northwestern University, Chicago.
Target Audience: This activity has been designed to meet the educational needs of physicians, advanced practice providers, and allied health professionals who provide care for hospitalized patients with liver disease.
Learning Objectives: After completing this program, participants should be better able to:

• Understand the complications and the consequences of cirrhosis.
• Describe the economic, patient, and caregiver burdens associated with cirrhosis.
• Demonstrate the ability to properly treat the complications of cirrhosis and prevent recurrence.

Accredited by: Rehoboth McKinley Christian Health Care Services
Provided by: Chronic Liver Disease Foundation. Supported by educational grants from Mallinckrodt Pharmaceuticals and Salix Pharmaceuticals.
Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the New Mexico Medical Society (NMMS) through the joint providership of Rehoboth McKinley Christian Health Care Services (RMCHCS), the Chronic Liver Disease Foundation, and the Texas Gulf Coast Gastroenterological Society. RMCHCS is accredited by the NMMS to provide continuing medical education for physicians. RMCHCS designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Americans with Disabilities Act: The event staff will be glad to assist you with any special needs (such as physical or dietary).
Registration: www.ChronicLiverDisease.org. On-site registration is available. Space is limited, so please arrive by 5:00 p.m. Seating is on a first-come, first-served basis.

An evidence-based approach to reducing stroke risk in nonvalvular atrial fibrillation
Sunday, March 24
5:30 - 7:30 p.m., Woodrow Wilson BC
Presenter:
Dharmesh Patel, MD, MBBS (London), FACC, FACP, FASPC, FNLA, Stern Cardiovascular Foundation; president of Alliance for Patient Access; past president American Heart Association; past chairman of medicine, Baptist Desoto Hospital, Southaven, Miss.; board member, AHA Southeast America, Memphis, Tenn.
Learning Objectives: This lecture will present options for reducing the risk of stroke in patients with nonvalvular atrial fibrillation.
Sponsored by: Janssen Pharmaceuticals.

Understanding your legal tools: The keys to lawsuit prevention, license protection and tax reduction
​​​​​​Monday, March 25
Noon - 1:00 p.m., National Harbor 2-3
Lunch provided at noon.
Objectives:

• Learn how to protect your license from negative reports to the NPDB following a settlement from your insurance company. If there is no NPD report, it’s unlikely that a board investigation into legal matters will materialize, preventing any sanctions from the state licensing board.
• Learn the best business structure for income tax reduction. Learn about the new tax laws passed in 2018 and how they can benefit you.
• Learn the use of legal tools that will protect your professional and personal assets from lawsuits. (Statistically, not even one in 100,000 are using these tools in the right way.)
• Learn how to protect business, property and personal assets in the event of a judgment in excess of liability insurance.
• Shows how to structure: C-corps, S-corps, FLPs, LLCs, etc. 

Faculty: Art McOmber
Sponsored by: Legally Mine.

Evidence-based approach to COPD management: Exploring new guidelines and treatment options for managing COPD exacerbations
Monday, March 257:00 - 9:30 p.m.,
Cherry Blossom Ballroom
Dinner provided at 7:00 p.m.
Learning Objectives: After completing this program, participants should be better able to do the following:

• Discuss considerations for reducing the risk of exacerbations in the inpatient and ambulatory setting.
• Raise awareness of strategies to improve COPD standardization of care across sites of care.
• Evaluate the role of long-acting bronchodilators to treat underlying pathophysiology of exacerbations.
• Understand the importance of inhaler selection when initiating maintenance therapy or reassessing treatment based on disease progression.

Faculty: Haley M. Hoy, PhD, ACNP, FAANP, The University of Alabama Huntsville, Vanderbilt Medical Center.
Sponsored by: Boehringer Ingelheim.

C. difficile infection: A hospitalist’s roadmap to treatment and prevention of recurrence 
Monday, March 25
7:00 - 9:00 p.m., National Harbor 2-3
Dinner provided at 7:00 p.m.
Program Overview: Clostridium difficile infection (CDI) places a significant clinical and economic burden on the health care system. The rising incidence of CDI is attributed to the emergence of a previously rare and hypervirulent strain of C. difficile. Increased toxin production and high-level antimicrobial resistance have allowed this strain to thrive in health care settings. Furthermore, populations previously thought to be at low risk of infection are now being identified as having severe CDI, including those without any exposure to health care facilities.

Fortunately, new diagnostic techniques have been developed to assist clinicians in the accurate and rapid detection of these infections. Additionally, new treatment options are available to clinicians for the management of initial and recurrent episodes of CDI. The prevention and management of CDI involve multiple disciplines responsible for the care of at-risk patients. As a key patient advocate in the hospital, the hospitalist can play a major role in ensuring that appropriate measures are in place for their patients at high risk for CDI. Hospitalists also can ensure that timely and appropriate diagnostic tests are performed at the early signs of CDI and that appropriate treatment selection is based on patient factors.
Faculty: William Ford, MD, SFHM, regional director hospital medicine and clinical associate professor of medicine, Abington (Penn.) Jefferson Health; Jason C. Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, clinical professor and clinical specialist, infectious diseases, and director, PGY2 Residency in Infectious Diseases Pharmacy, Temple University, Philadelphia; Ciaran P. Kelly, MD, professor of medicine, Harvard Medical School, and director, gastroenterology fellowship training and director, Celiac Center, Beth Israel Deaconess Medical Center, both in Boston.
Registration: www.vemcomeded.com/livemeetings.asp or call 908-704-2400.
Accreditation statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Center for Independent Healthcare Education (Center) and Vemco MedEd. Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit designation: Center designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supported by an educational grant from Merck & Co. Jointly provided by Center for Independent Healthcare Education and Vemco MedEd.

Hepatology News Tonight: Managing complications of cirrhosis
Sunday, March 24
5:30 - 7:30 p.m., National Harbor 4-5
Registration starts at 5:30 p.m. Dinner Symposium 6:00 - 7:30 p.m.
Presenters:Robert S. Brown Jr., MD, MPH (Chair), Gladys and Roland Harriman professor of medicine, vice chair for mentorship and academic development, clinical chief of the division of gastroenterology & hepatology, Weill Cornell Medicine, New York; Kimberly Brown, MD, FAST, FAASLD, AGAF, professor of medicine at Wayne State University and chief of gastroenterology and hepatology and associate medical director, Henry Ford Hospital Transplant Institute, Henry Ford Hospital, both in Detroit; Steven Flamm, MD, FAASLD, FACG, chief, liver transplantation program, and professor of medicine and surgery, Northwestern University, Chicago.
Target Audience: This activity has been designed to meet the educational needs of physicians, advanced practice providers, and allied health professionals who provide care for hospitalized patients with liver disease.
Learning Objectives: After completing this program, participants should be better able to:

• Understand the complications and the consequences of cirrhosis.
• Describe the economic, patient, and caregiver burdens associated with cirrhosis.
• Demonstrate the ability to properly treat the complications of cirrhosis and prevent recurrence.

Accredited by: Rehoboth McKinley Christian Health Care Services
Provided by: Chronic Liver Disease Foundation. Supported by educational grants from Mallinckrodt Pharmaceuticals and Salix Pharmaceuticals.
Accreditation Statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the New Mexico Medical Society (NMMS) through the joint providership of Rehoboth McKinley Christian Health Care Services (RMCHCS), the Chronic Liver Disease Foundation, and the Texas Gulf Coast Gastroenterological Society. RMCHCS is accredited by the NMMS to provide continuing medical education for physicians. RMCHCS designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Americans with Disabilities Act: The event staff will be glad to assist you with any special needs (such as physical or dietary).
Registration: www.ChronicLiverDisease.org. On-site registration is available. Space is limited, so please arrive by 5:00 p.m. Seating is on a first-come, first-served basis.

An evidence-based approach to reducing stroke risk in nonvalvular atrial fibrillation
Sunday, March 24
5:30 - 7:30 p.m., Woodrow Wilson BC
Presenter:
Dharmesh Patel, MD, MBBS (London), FACC, FACP, FASPC, FNLA, Stern Cardiovascular Foundation; president of Alliance for Patient Access; past president American Heart Association; past chairman of medicine, Baptist Desoto Hospital, Southaven, Miss.; board member, AHA Southeast America, Memphis, Tenn.
Learning Objectives: This lecture will present options for reducing the risk of stroke in patients with nonvalvular atrial fibrillation.
Sponsored by: Janssen Pharmaceuticals.

Understanding your legal tools: The keys to lawsuit prevention, license protection and tax reduction
​​​​​​Monday, March 25
Noon - 1:00 p.m., National Harbor 2-3
Lunch provided at noon.
Objectives:

• Learn how to protect your license from negative reports to the NPDB following a settlement from your insurance company. If there is no NPD report, it’s unlikely that a board investigation into legal matters will materialize, preventing any sanctions from the state licensing board.
• Learn the best business structure for income tax reduction. Learn about the new tax laws passed in 2018 and how they can benefit you.
• Learn the use of legal tools that will protect your professional and personal assets from lawsuits. (Statistically, not even one in 100,000 are using these tools in the right way.)
• Learn how to protect business, property and personal assets in the event of a judgment in excess of liability insurance.
• Shows how to structure: C-corps, S-corps, FLPs, LLCs, etc. 

Faculty: Art McOmber
Sponsored by: Legally Mine.

Evidence-based approach to COPD management: Exploring new guidelines and treatment options for managing COPD exacerbations
Monday, March 257:00 - 9:30 p.m.,
Cherry Blossom Ballroom
Dinner provided at 7:00 p.m.
Learning Objectives: After completing this program, participants should be better able to do the following:

• Discuss considerations for reducing the risk of exacerbations in the inpatient and ambulatory setting.
• Raise awareness of strategies to improve COPD standardization of care across sites of care.
• Evaluate the role of long-acting bronchodilators to treat underlying pathophysiology of exacerbations.
• Understand the importance of inhaler selection when initiating maintenance therapy or reassessing treatment based on disease progression.

Faculty: Haley M. Hoy, PhD, ACNP, FAANP, The University of Alabama Huntsville, Vanderbilt Medical Center.
Sponsored by: Boehringer Ingelheim.

C. difficile infection: A hospitalist’s roadmap to treatment and prevention of recurrence 
Monday, March 25
7:00 - 9:00 p.m., National Harbor 2-3
Dinner provided at 7:00 p.m.
Program Overview: Clostridium difficile infection (CDI) places a significant clinical and economic burden on the health care system. The rising incidence of CDI is attributed to the emergence of a previously rare and hypervirulent strain of C. difficile. Increased toxin production and high-level antimicrobial resistance have allowed this strain to thrive in health care settings. Furthermore, populations previously thought to be at low risk of infection are now being identified as having severe CDI, including those without any exposure to health care facilities.

Fortunately, new diagnostic techniques have been developed to assist clinicians in the accurate and rapid detection of these infections. Additionally, new treatment options are available to clinicians for the management of initial and recurrent episodes of CDI. The prevention and management of CDI involve multiple disciplines responsible for the care of at-risk patients. As a key patient advocate in the hospital, the hospitalist can play a major role in ensuring that appropriate measures are in place for their patients at high risk for CDI. Hospitalists also can ensure that timely and appropriate diagnostic tests are performed at the early signs of CDI and that appropriate treatment selection is based on patient factors.
Faculty: William Ford, MD, SFHM, regional director hospital medicine and clinical associate professor of medicine, Abington (Penn.) Jefferson Health; Jason C. Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, clinical professor and clinical specialist, infectious diseases, and director, PGY2 Residency in Infectious Diseases Pharmacy, Temple University, Philadelphia; Ciaran P. Kelly, MD, professor of medicine, Harvard Medical School, and director, gastroenterology fellowship training and director, Celiac Center, Beth Israel Deaconess Medical Center, both in Boston.
Registration: www.vemcomeded.com/livemeetings.asp or call 908-704-2400.
Accreditation statement: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Center for Independent Healthcare Education (Center) and Vemco MedEd. Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit designation: Center designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supported by an educational grant from Merck & Co. Jointly provided by Center for Independent Healthcare Education and Vemco MedEd.